PEA Complex: palmitoylethanolamide and boswellia
endogenous pain regulation and broad inflammation modulation
How does PEA work as a body’s own pain-regulating molecule, what makes the combination with boswellia mechanistically unique, and why is this a more sustainable alternative than NSAIDs for chronic pain in dogs, cats and humans? Substantiated with recent literature.
By Stefan Veenstra DVM
PEA: the body’s own pain-regulating molecule
Palmitoylethanolamide (PEA) is a fatty acid amide that belongs to the family of N-acylethanolamines and occurs naturally in virtually all mammalian tissues. The body produces PEA locally on demand in response to tissue damage, infection, and inflammation, via enzymatic hydrolysis of membrane phospholipids. This “on demand” manufacturing principle fundamentally differentiates PEA from pharmacological painkillers: it is an endogenous regulator that is already part of the body’s physiological pain modulation systems. [1]
In chronic inflammation and chronic pain, endogenous PEA levels drop while demand increases. Supplementation with exogenous PEA supplements this deficiency and restores the pain-modulating function that the body can no longer provide sufficiently. Della Rocca and Gamba (2021) describe in their review in Animals how this mechanism works identically in dogs and cats as in humans: the biosynthetic and degradative machinery for PEA is present in dog and cat tissue and responds to the same cell biological stimuli. [2]
NGD Care Joint Protocol: PEA as a Core of Pain and Inflammation Modulation
NGD Care Skin Protocol: PEA for Chronic Skin Inflammation and Atopy
NGD Care Surgery Recovery Package: Post-operative Inflammation Modulation
NGD Care Intracellular Microbe Protocol: Nervous System and Inflammation Support
The three mechanisms of action of PEA
PPAR-alpha activation: anti-inflammatory gene expression
The primary receptor for PEA is PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear transcription factor that regulates the expression of pro-inflammatory genes. Activation of PPAR-alpha by PEA decreases the production of TNF-alpha, IL-1 beta, IL-6 and COX-2 via NF-kB inhibition, giving broad anti-inflammatory effects without the immunosuppressive side effects of corticosteroids. [3] This mechanism is active in both peripheral tissues and the central nervous system, making PEA one of the few substances that can address both peripheral and central sensitization in chronic pain.
Mast cell inhibition: peripheral grafting modulation
Mast cells are central mediators of peripheral inflammation in allergic skin reactions, joint inflammation, and neuropathic pain. PEA inhibits mast cell degranulation via PPAR-alpha activation and indirectly via modulation of the endocannabinoid system (CB2 receptor). Less mast cell degranulation means less histamine, prostaglandins and proteases in the affected tissue, which directly dampens the local inflammatory response. [3] This mechanism is particularly relevant in atopic dermatitis in dogs and cats, where mast cell activity plays a central role.
Glial cell modulation: central and neuropathic pain reduction
Chronic pain is maintained not only by peripheral inflammation but also by overactivation of microglia and astrocytes in the spinal cord and brain. This phenomenon, known as central sensitization, explains why chronic pain persists even when the peripheral cause has been removed. PEA modulates glial cell activity via PPAR-alpha and has demonstrated neuroprotective effects in models of neuropathic pain, multiple sclerosis, and neurodegenerative disorders. [4] In animals with chronic pain following infection, surgery, or nerve damage, glial cell modulation is a mechanistically relevant target that conventional NSAIDs do not provide.
Veterinary Clinical Evidence for PEA
The veterinary literature for PEA has grown significantly over the past five years. A double-blind, placebo-controlled, randomized clinical trial published in Frontiers in Veterinary Science (2026) showed significant reductions in pain symptoms and pain impact scores after PEA supplementation over 12 weeks compared to placebo in 50 dogs and 50 cats with joint pain. [5]
Overview of veterinary clinical trials for PEA
Frontiers in Veterinary Science (2026): RCT in 100 dogs and cats with joint pain. Significant pain reduction vs. placebo at 12 weeks. [5]
Gugliandolo et al., Veterinary Sciences (2022): Improvement in pain scores and quality of life in dogs with chronic osteoarthritis after PEA-containing formulation.[6]
Noli et al., Veterinary Dermatology (2015): Effectiveness of ultra-micronized PEA in canine atopic dermatitis in an open-label multicenter study.[7]
Della Rocca and Gamba, Animals (2021): Review of all clinical evidence for micro-PEA in chronic pain in dogs and cats, with mechanistic background.[2]
Boswellia serrata: complementary inflammatory pathway
Boswellia serrata, also known as Indian frankincense, provides boswellic acids (specifically AKBA: 3-O-acetyl-11-keto-beta-boswellic acid) that selectively inhibit 5-lipoxygenase (5-LOX). 5-LOX is the enzyme that converts arachidonic acid to leukotrienes (in particular LTB4), powerful pro-inflammatory mediators that play a central role in joint inflammation, IBD, airway inflammation and atopic reactions. [8]
The distinction with NSAIDs is mechanistically important: NSAIDs primarily inhibit cyclooxygenase (COX-1 and COX-2), blocking prostaglandin synthesis but leaving the leukotriene pathway untouched. Boswellia selectively inhibits 5-LOX and thus leukotrienes, without the COX pathway and therefore without the gastrointestinal and renal side effects that are a real clinical problem in dogs and cats with long-term NSAID use. [8]
Synergy of PEA and boswellia
PEA and boswellia act through fully complementary mechanisms on the inflammatory cascade. PEA modulates the cellular origin of inflammation (mast cells, microglia, macrophages via PPAR-alpha) and addresses central sensitization. Boswellia blocks a specific biochemical pathway (5-LOX) that does not or barely touches PEA. Together, they provide broader inflammation modulation than either individually, covering both the cellular and biochemical dimensions of chronic pain and inflammation.
Why PEA Complex is more durable than NSAIDs in chronic use
NSAIDs are effective in acute inflammation but have known and clinically relevant side effects in dogs and cats when used over a long period of time: gastrointestinal erosions and ulcers (COX-1 inhibition), renal decline (prostaglandin-dependent renal autoregulation), and hepatotoxicity with some specific agents. In chronic conditions that require months or lifelong treatment, such as osteoarthritis, IBD, and atopic dermatitis, these side effects are a real clinical problem. [9]
PEA and boswellia do not or hardly inhibit the COX route. In several clinical studies, no relevant toxicity has been demonstrated with long-term use of PEA in dogs and cats. This makes PEA Complex suitable as long-term monotherapy for mild to moderate chronic pain, or as an adjunct to lower NSAID dosages for more severe complaints, reducing the overall NSAID burden.
Application area PEA Complex: dog, cat and human
Osteoarthritis and joint pain at all stages and breeds. Chronic intestinal inflammation (IBD) and bowel-related pain. Neuropathic pain and central sensitization after infection or surgery. Atopic dermatitis and chronic skin inflammation. Airway inflammation and chronic coughing. Post-operative inflammation modulation as an alternative to NSAIDs. Chronic immune activation in long-term infections (part of the Intracellular Microbe Protocol). Long-term pain treatment where NSAID side effects are a concern. Always consult with an (integrative) veterinarian in case of serious or progressive complaints.
Conclusion
PEA Complex combines two complementary anti-inflammatory mechanisms: PEA via PPAR-alpha activation, mast cell inhibition and glial cell modulation, and boswellia via selective 5-LOX inhibition. Together, they provide broader pain and inflammation modulation than each individually, without the side effects of COX-inhibiting NSAIDs with long-term use.
The clinical veterinary evidence for PEA has grown significantly in recent years, with multiple controlled studies demonstrating effectiveness in osteoarthritis and atopic dermatitis in dogs and cats. PEA Complex is suitable as a long-term treatment for chronic pain and inflammation, as a monotherapy or as an addition to existing treatment. Always in consultation with an (integrative) veterinarian.
View NGD Care PEA Complex in the webshop
Literature
- Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017; 174(11):1349–1365.
- Della Rocca G, Gamba D. Chronic pain in dogs and cats: is there place for dietary intervention with micro-palmitoylethanolamide? Animals. 2021; 11(4):952.
- Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005; 67(1):15–19.
- Skaper SD, Facci L, Zusso M, Giusti P. Neuroinflammation, mast cells, and glia: dangerous liaisons. Neuroscientist. 2017; 23(5):478–498.
- Levagen+ (palmitoylethanolamide) alleviates joint pain and reduces the impact of joint pain in canines and felines: a double-blind, placebo-controlled, randomized clinical trial. Front Vet Sci. 2026. doi:10.3389/fvets.2026.1703143. [Most Recent Veterinary RCT PEA in Dogs and Cats, 2026]
- Gugliandolo E, Fusco R, D’Amico R, et al. Effect of a new oral composition based on palmitoylethanolamide on pain score and quality of life in dogs affected by chronic osteoarthritis. Fat Sci. 2022; 9(2):59.
- Noli C, Della Valle MF, Miolo A, et al. Efficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre study. Fat Dermatol. 2015; 26(6):432–440.
- Siddiqui MZ. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharm Sci. 2011; 73(3):255–261.
- Lascelles BD, Blikslager AT, Fox SM, Reece D. Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002–2003). J Am Vet Med Assoc. 2005; 227(7):1112–1117.
This information is educational in nature and based on available scientific literature. The studies mentioned are not always directly veterinary or specific to the formulation described here. This text does not replace a veterinary consultation and does not contain any therapeutic claims.